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OBJECTIVES: The aim of this study was to examine the frequency of Cushing’s syndrome (CS) in obese patients devoid of 
specific clinical symptoms of Cushing’s syndrome. 
METHODS: A total of 150 obese patients (129 female, 21 male; mean age 44.41 ± 13.34 yr; mean BMI 35.76 ± 7.13) were in-
cluded in the study. As a first screening step, we measured 24-h urinary free cortisol (UFC). An overnight 1-mg dexamethasone 
suppression test was also performed on all patients. Urinary free cortisol levels above 100 µg/24 h were considered to be abnormal. 
Suppression of serum cortisol <1.8 µg/dL after administration of 1 mg dexamethasone was the cut-off point for normal suppression. 
The suppression of the serum cortisol levels failed in all of the patients. 
RESULTS: Measured laboratory values were as follows: ACTH, median level 28 pg/ml, interquartile range (IQR) 14-59 pg/ml; 
fasting glucose, 100 (91-113) mg/dL; insulin, 15.7 (7.57-24.45) mU/ml; fT4, 1.17 (1.05-1.4) ng/dL; TSH, 1.70 (0.91-2.90) mIU/L; 
total cholesterol, 209 (170.5-250) mg/dL; LDL-c, 136 (97.7-163) mg/dL; HDL-c, 44 (37.25-50.75) mg/dL; VLDL-c, 24 (17-36) 
mg/dL; triglycerides, 120.5 (86-165) mg/dL. The median UFC level of the patients was 30 µg/24 h (IQR 16-103). High levels of 
UFC (>100 µg/24 h) were recorded in 37 patients (24%). Cushing’s syndrome was diagnosed in 14 of the 150 patients (9.33%). 
Etiologic reasons for Cushing’s syndrome were pituitary microadenoma (9 patients), adrenocortical adenoma (3 patients), and 
adrenocortical carcinoma (1 patient). 
CONCLUSION: A significant proportion (9.33%) of patients with simple obesity were found to have Cushing’s syndrome. These 
findings argue that obese patients should be routinely screened for Cushing’s syndrome. 
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INTRODUCTION
Obesity is the most common metabolic problem in 
industrialized countries. In the USA, 32% of adults are 
classified as overweight, and 22.5% of these individuals 
are obese.1 Both overweight and obese subjects are at an 
increased risk for cardiovascular diseases,2 some types of 
cancer,3 diabetes4, and even premature death.5 Obesity is 
often accompanied by other chronic disorders including 
hypertension, osteoarthritis, bile stones, and dyslipidemia.6-12 
In addition to these physical disorders, obesity is commonly 
associated with psychological and psycho-social problems.10
Obesity can coexist with diverse physical disorders, 
and physicians should first focus on the differential 
diagnosis of possible underlying disorders before initiating 
any management procedure. Obesity is a prominent 
feature of endocrine diseases including hypothyroidism, 
insulin-excess syndromes, polycystic ovary syndrome 
(PCOS), hypogonadism, hypothalamic disease/injury, 
growth hormone deficiency, leptin deficiency or leptin 
receptor defects, pseudohypoparathyroidism, and Cushing’s 
syndrome (CS).11,12
Diagnosis of CS is primarily based on the signs and 10
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symptoms of the disorder. Nevertheless, a significant number 
of CS patients present only with simple obesity13-14 or with 
type 2 diabetes mellitus and poor glycemic control.15-17 
Metabolic syndrome may also indicate the presence of CS. 
Patients without specific clinical features of CS have been 
referred to as sub-clinical Cushing’s syndrome (SCS)15 
patients, and the diagnosis of SCS affords a considerable 
challenge to the physician.
We accordingly set out to determine the frequency of CS 
in patients presenting with simple obesity in the absence of 
other specific signs or symptoms indicative of CS.
PATIENTS AND METHODS
This study included 150 consecutive simple obese 
patients (129 female, 21 male, mean age: 44.41 ± 13.34 yr, 
body mass index (BMI) > 25 kg/m2) who were followed 
and treated at the Endocrinology Metabolism outpatient 
clinic at Cerrahpasa Medical Faculty between June 2003 
and June 2004. Written informed consent was obtained from 
all patients before commencement of the study. Review 
of patient medical history was used to exclude subjects in 
which the dexamethasone suppression test could be biased 
either by medication (including exogenous glucocorticoid 
intake) or by other factors known to influence the test 
(including drug use, alcoholism, obvious depression, or 
pregnancy). None of the patients had nephropathy (creatinine 
clearance <30 ml/min), acute illness, or sleep disorders.
All patients in our study had simple obesity; none of 
them had diabetes mellitus. Since the patients had simple 
obesity, careful examinations did not reveal hirsutism, 
buffalo hump, easy bruising, or any other manifestations 
suggestive of CS suggestive manifestations. 
Clinical  characteristics  recorded  included  BMI 
and anthropometric measurements. Morning blood 
samples following fasting (12 h) were drawn from an 
antecubital vein for determination of the concentrations 
of adrenocorticorticotropic hormone (ACTH) (N: 0-46 
pg/ml), cortisol (N: 5-28 µg/dL), glucose, insulin (N: 
0-20 µIU/L), serum lipids (total cholesterol, LDL, HDL, 
VLDL-cholesterol, and triglyceride), free thyroxin (fT4) 
(N: 0.93-1.77 ng/dL), and thyrotropin (TSH) (N: 0.15-3.7 
IU/ml). Urine (24 h) was collected from each subject in 
order to perform urinary free cortisol (UFC) measurements. 
Patients whose 24-h UFC excretion exceeded 100µg/
dL were defined as abnormal. All patients subsequently 
underwent a 1-mg overnight dexamethasone suppression 
test (DMS). Suppression of serum cortisol to <1.8 µg/dL 
after dexamethasone administration was the cut-off point 
for normal suppression without consideration of 24-h UFC. 
Measurement of serum ACTH levels and an 8-mg DMS 
were performed as second-step investigations in all patients 
who failed to achieve serum cortisol suppression <1.8 µg/
dL after administration of 1 mg DMS. Complementary 
imaging studies, magnetic resonance imaging (MRI) of the 
sella, cavernous sinus sampling, and abdominal computed 
tomography (CT) were performed when the results of 
the second-step evaluations were consistent with ACTH-
dependent or ACT-independent CS. 
Insulin, cortisol, fT4, TSH, and ACTH were assessed 
by radioimmunoassay (RIA) using a Packard Riastar 
gamma counter (Perkin-Elmer, Waltham, MA, USA) and 
commercial assay kits. Other biochemical laboratory tests 
were measured with an Olympus AU 600 autoanalyser 
(Olympus, Tokyo, Japan). Insulin resistance was assessed 
using the homeostasis model assessment ratio (HOMA-R) 
formula (18). 
Calculations were done with SPSS software (version 10; 
SPSS Inc, Chicago, IL, USA), and differences in the values 
of the variables between the groups were evaluated by the 
Mann-Whitney U test. The degree of the correlation between 
parameters was evaluated by regression analysis. A value of 
p<0.05 was considered to be statistically significant. 
RESULTS
We analyzed a series of patients presenting with simple 
obesity for the presence of sub-clinical CS. The clinical 
characteristics and laboratory findings for these patients are 
summarized in Tables 1 and 2.
In 37 patients (24%), 24-h UFC excretion exceeded the 
cut-off point (median, 30; interquartile range (IQR), 16-103 
µg/24 h). Fourteen patients had unsuppressed cortisol levels 
as indicated by the 1-mg dexamethasone suppression test. 
Complementary imaging studies were performed on these 
14 CS patients, which revealed pituitary microadenoma 
in 9 patients, adrenal adenoma in 3 patients, and adrenal 
carcinoma in 1 patient. Histological diagnosis was obtained 
in 13 patients; one patient declined to undergo surgical 
intervention for definitive diagnosis (Table 3).
Table 1 - Summary of physical examination findings in the 
patient group
(Mean ± SD) (n=150)
BMI (kg/m2) 35.76 ± 7.13
Waist (cm) 104.07 ± 15.77
Waist-to-hip ratio 0.98 ± 0.92
Systolic blood pressure (mm/Hg) 135.13 ± 20.49
Diastolic blood pressure (mm/Hg) 87.23 ± 13.0311
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Table 2 - Laboratory findings in the study patients
Simple 
obesity
Cushing’s 
syndrome
p
ACTH (pg/ml) 25.7
 [15-51]
35
 [13.5-94.5]
0.43
Cortisol (µg/dL) 10.2
 [7.8-14.8]
9.4
 [8.1-13.5]
0.88
Glucose (mg/dL) 99 
[91-113]
100 
[93.5-114]
0.91
Insulin (mU/ml) 14.7 
[7.4-24.2]
18.9
 [14.9-28.5]
0.07
f T4 (ng/dL) 1.2
 [1.07-1.4]
1.1
 [1.04-1.63]
0.56
TSH (mIU/L) 1.64 
[0.9-2.8]
1.78 
[1.6-4.2]
0.25
Cholesterol (mg/dL) 203
 [172-249]
238.5
[178.-264]
0.24
LDL-c (mg/dL) 129 
[97-159]
168
 [122-168]
0.15
HDL-c (mg/dL) 44 
[37.5-50.5]
46 
[29-66]
0.72
VLDL-c (mg/dL) 24
 [17-33]
38 
[16.2-50]
0.2
Triglyceride (mg/dL) 120
 [86-161]
208
[89.8-251]
0.15
Urine cortisol (µg/24 h) 28
 [15-92.5]
74 
[27-133]
0.02
DMST cortisol (µg/dL) 0.88
 [0.7-1.15]
3.35
 [2.5-6.5]
< 0.0001
HOMA-R
(mg/dl x mU/ml)
4.02
[1.91-6.59]
4.66
[4.38-9.08]
0.06
Values are medians and interquartile ranges.
DMST: 1-mg dexamethasone suppression test
Table 3 - Etiologies of the 14 patients diagnosed with Cush-
ing’s syndrome
N %
Pituitary adenoma 9 64.28
Surrenal cortex adenoma 3 21.42
Surrenal cortex carcinoma 1 7.15
Declined further evaluation 1 7.15
Figure 1 - Twenty-four-hour free cortisol levels in patients with Cushing’s 
syndrome and simple obesity
Figure 2 - The comparison of the 1-mg dexamethasone suppression test 
results for both groups
We compared the group of 14 obese patients with CS 
to the remaining group of 136 patients with simple obesity. 
There was no significant difference in levels of ACTH 
(p=0.43) or basal cortisol (p=0.88) between the CS group 
and the group of simple obese patients without CS. However, 
24-h UFC excretion (Figure 1) and morning cortisol levels 
following administration of 1 mg DMS (Figure 2) were 
significantly more elevated in obese patients with CS than 
in simple obese patients without CS.
There were no significant differences between the groups 
in mean values for serum lipids, glucose, BMI, systolic 
blood pressure, or waist-to-hip ratio. Diastolic pressure 
was higher in patients with CS (p=0.02). Although higher 
HOMA-R values were recorded in patients with CS (median, 
4.66 mg/dL x mU/ml; IQR, 1.38-9.08) compared to simple 
obese patients (median, 4.02 mg/dL x mU/ml; IQR, 1.91-
6.59), the difference between the two groups narrowly failed 
to achieve statistical significance (p=0.06). 
DISCUSSION 
Here, we report on 150 obese patients screened for CS. 
A diagnosis of CS was established in 14 patients (9.33%). 
This finding confirms the need to evaluate patients with 
simple obesity for CS despite the absence of other signs or 
symptoms of the disorder.
This conclusion is supported by several previous 
studies. Obesity is a frequent clinical sign of CS, and 
adipose tissues in CS patients typically have a central 
distribution. Obese patients with CS may live without any 
evident metabolic disorder associated with CS. However, 12
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CS screening in simple obesity is usually not performed 
unless the patient has other clinical features of CS, such 
as poorly controlled hypertension, diabetes, osteoporosis 
with rapid progression, or hypokalemia that is unresponsive 
to the therapy. Delayed identification of SCS in obese 
patients results in the progression of CS, with the risk of 
irreversible complications. We therefore initiated a screening 
program for CS in our simple obese outpatients. The use of 
sensitive assays resulted in a significant improvement in the 
identification of CS. We documented 14 cases of CS in a 
sample of 150 simple obese patients. The high proportion of 
patients with Cushing’s syndrome that we identified despite 
the rareness of CS could be because we screened for CS in 
an obese population. These findings argue that every patient 
with simple obesity should be investigated for CS. 
Some patients with type 2 diabetes and poor glycemic 
control may also have subclinical CS (SCS), and these 
patients should be screened for CS. Recent studies have 
provided a rationale for the systemic screening of CS in 
patients with type 2 diabetes.16,17 Hypercortisolism can result 
in insulin resistance; glucose intolerance (or type 2 diabetes) 
secondary to insulin resistance occurs in approximately 75% 
of patients with CS. In this subgroup, 50% of the subjects 
had overt type 2 diabetes (20-25% of all CS patients). It has 
been well documented since the 1960s that patients with CS 
typically suffer from hyperinsulinemia, insulin resistance, 
and type 2 diabetes.19,20
 Catargi et al. screened 200 overweight inpatients with 
type 2 diabetes and poor glycemic control (HbA1c >8%).15 
None displayed the specific clinical features of CS in 
addition to their poorly-controlled type 2 diabetes. A total 
of 52 (26%) patients had impaired 1-mg DMS (failure 
to suppress cortisol <2.1 µg/dL). Of these, 17 (8.5%) 
displayed at least one additional biological abnormality of 
the hypothalamic-pituitary-adrenal axis. Imaging studies 
showed abnormalities in 11 of these 17 patients (5.5% of 
the whole series). Definitive occult CS was identified in 
4 patients (2%), with 3 (1.5%) having Cushing’s disease 
and 1 (0.5%) with surgically proven adrenal adenoma. 
However, definitive diagnosis of CS in the remaining seven 
patients (3.5%) required further investigation. A unilateral 
adrenal tumor of 10-29 mm was subsequently revealed by 
abdominal CT and iodocholesterol scintigraphy. These 
seven patients, therefore, had probable adrenal-dependent 
CS but did not undergo surgery. Six months after treatment 
for CS, a mean 5.5% reduction in body weight and a mean 
2.5% reduction in HbA1c were reported in four patients. 
Oral antidiabetic medications were resumed in one patient, 
and the daily insulin dose was dramatically reduced 
in another. This study highlights the need to perform 
prospective CS screening on overweight, poorly controlled 
type 2 diabetic patients. 15
Assessment of 24-h UFC is a convenient screening test 
for CS in outpatient clinics. The false-negative rate for UFC 
is extremely low, though false-positive rates tend to be high. 
CS can, therefore, be excluded if 24-h UFC is normal. In 
patients with elevated 24-h UFC levels, a diagnosis of CS 
should be confirmed by a 1-mg overnight dexamethasone 
suppression test. In our study group, only 14 of 30 patients 
having elevated UFC were confirmed as having CS by the 
1-mg DMS test. The remaining 16 obese patients were 
considered to be false-positives. Wood et al. established 
that suppression of plasma cortisol to less than 1.8 µg/dL 
excluded CS without an increase in the false-positive rate. 
21 A study by Baid SK et al. demonstrated that the results of 
screening tests specific to CS may be falsely abnormal in 
overweight and obese populations.22 
In our study, definitive CS was identified in 13 of 14 
patients with unsuppressed serum cortisol after the results 
of the 1-mg DMS test were considered. One patient declined 
further investigation. The remaining 13 patients underwent 
further biochemical and imaging studies. Definitive 
diagnoses of CS were proven by histological analysis of 
surgically-removed material. Among 30 patients with 
elevated 24-h UFC, levels were significantly more elevated 
in the group of patients with unsuppressed cortisol after 
administration of 1 mg DMS (p=0.002) than in simple obese 
patients with suppressed cortisol levels. 
Distinguishing simple obese patients from CS presents a 
challenge for the physician. Future studies on larger patient 
populations will be required to address the true prevalence 
of CS. Appropriate study groups will include patients with 
relevant clinical features, including simple obesity, poorly 
controlled diabetes, osteoporosis, and PCOS. 
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